IDEAYA Biosciences announced positive topline results from the Phase 2/3 OptimUM-02 trial of darovasertib combined with crizotinib for first-line HLA*A2-negative metastatic uveal melanoma, showing a 58% reduction in disease progression risk and improved progression-free survival. The company plans to submit a New Drug Application (NDA) to the FDA in the second half of 2026, aiming for accelerated approval under the Real-Time Oncology Review program. Additional clinical updates for other pipeline candidates are expected in H2 2026, and IDEAYA maintains a strong cash reserve of approximately $973 million, supporting operations into 2030.
Tether CEO Paolo Ardoino highlighted growing reliance on the USDT stablecoin in countries like Venezuela, Argentina, Bolivia, and Turkey due to inflation, currency depreciation, and limited access to physical dollars. These economies use USDT for dom...
Upbit will launch a South Korean won (KRW) trading market for Lighter's LIT token on August 24 at 1:00 pm KST. Initially, buy orders will be restricted for about five minutes and only limit orders will be allowed for the first two hours to prevent di...
US spot Bitcoin ETFs attracted nearly $1.92 billion in net inflows over the week ending August 22, marking their strongest weekly inflow since October 2025. This surge coincided with Bitcoin's price rally of 18% to 25%, testing levels near $80,000. B...
Different major cryptocurrencies use distinct consensus algorithms to validate transactions and secure their blockchains. Bitcoin pioneered Nakamoto Consensus, relying on proof-of-work mining and cumulative computational effort to confirm transaction...
In 2026, buy now, pay later companies Sezzle and Klarna showed contrasting stock performances, with Sezzle rising 88% and Klarna dropping 50%. Sezzle's stronger profitability, with an adjusted EPS of $5.25 projected for 2026 and a price-to-earnings r...
